Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Common Equity (2016 - 2025)

Historic Common Equity for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $6.2 million.

  • Sangamo Therapeutics' Common Equity fell 8404.71% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year decrease of 8404.71%. This contributed to the annual value of $22.8 million for FY2024, which is 7252.89% down from last year.
  • Latest data reveals that Sangamo Therapeutics reported Common Equity of $6.2 million as of Q3 2025, which was down 8404.71% from $19.6 million recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' Common Equity ranged from a high of $469.4 million in Q1 2021 and a low of $4.9 million during Q1 2025
  • For the 5-year period, Sangamo Therapeutics' Common Equity averaged around $206.0 million, with its median value being $233.6 million (2023).
  • Its Common Equity has fluctuated over the past 5 years, first surged by 1901.6% in 2021, then crashed by 9134.7% in 2025.
  • Over the past 5 years, Sangamo Therapeutics' Common Equity (Quarter) stood at $375.3 million in 2021, then dropped by 21.42% to $295.0 million in 2022, then tumbled by 71.9% to $82.9 million in 2023, then tumbled by 72.53% to $22.8 million in 2024, then tumbled by 72.58% to $6.2 million in 2025.
  • Its Common Equity stands at $6.2 million for Q3 2025, versus $19.6 million for Q2 2025 and $4.9 million for Q1 2025.